Minerva Neurosciences, Inc.
NERVNASDAQHealthcare● Active
$4.57
$-0.06(-1.30%)
Market Cap$31957864
P/E Ratio—
52W High$12.46
52W Low$1.566
Minerva Neurosciences, Inc. (NERV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NERV · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.17
Est. -$0.13 · -30.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS
NERV reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.19 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 5, 2026 | -$0.13 | -$0.17 | -30.8% | — | — | — |
| ▼ Q1 FY2026 | Mar 11, 2026 | -$0.11 | -$0.64 | -481.8% | — | — | — |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.35 | -$0.36 | -2.9% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.95 | -$0.43 | +54.7% | — | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$1.07 | -$0.50 | +53.3% | — | — | — |
| ▲ Q1 FY2025 | Feb 25, 2025 | -$1.05 | -$0.56 | +46.7% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$1.01 | $2.97 | +394.1% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.19
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$0.17
EPS Est.
-$0.13
EPS Surpr.
-30.8%
Revenue
—
Q1 FY2026
Mar 11, 2026Miss
EPS Actual
-$0.64
EPS Est.
-$0.11
EPS Surpr.
-481.8%
Revenue
—
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$0.36
EPS Est.
-$0.35
EPS Surpr.
-2.9%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.43
EPS Est.
-$0.95
EPS Surpr.
+54.7%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.50
EPS Est.
-$1.07
EPS Surpr.
+53.3%
Revenue
—
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
-$0.56
EPS Est.
-$1.05
EPS Surpr.
+46.7%
Revenue
$0.00B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
$2.97
EPS Est.
-$1.01
EPS Surpr.
+394.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q3 FY2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q2 FY2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q1 FY2027 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q4 FY2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q3 FY2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -30.8% | $6.33 | $6.25 | -1.26% |
| ▼ Q1 FY2026 | Mar 11, 2026 | -481.8% | $7.94 | $7.30 | -8.06% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -2.9% | $3.67 | $3.82 | +4.09% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +54.7% | $1.81 | $1.80 | -0.55% |
| ▲ Q2 FY2025 | May 13, 2025 | +53.3% | $1.63 | $1.63 | +0.00% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +46.7% | $1.79 | $1.79 | +0.00% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +394.1% | $2.32 | $2.36 | +1.72% |
| ▼ Q3 FY2024 | Aug 6, 2024 | -12.4% | $2.80 | $2.94 | +5.00% |
Q2 FY2026-1.26%
Report Date
May 5, 2026
EPS Beat/Miss
-30.8%
Price Before
$6.33
Price After
$6.25
Q1 FY2026-8.06%
Report Date
Mar 11, 2026
EPS Beat/Miss
-481.8%
Price Before
$7.94
Price After
$7.30
Q4 FY2025+4.09%
Report Date
Nov 5, 2025
EPS Beat/Miss
-2.9%
Price Before
$3.67
Price After
$3.82
Q3 FY2025-0.55%
Report Date
Aug 14, 2025
EPS Beat/Miss
+54.7%
Price Before
$1.81
Price After
$1.80
Q2 FY2025+0.00%
Report Date
May 13, 2025
EPS Beat/Miss
+53.3%
Price Before
$1.63
Price After
$1.63
Q1 FY2025+0.00%
Report Date
Feb 25, 2025
EPS Beat/Miss
+46.7%
Price Before
$1.79
Price After
$1.79
Q4 FY2024+1.72%
Report Date
Nov 5, 2024
EPS Beat/Miss
+394.1%
Price Before
$2.32
Price After
$2.36
Q3 FY2024+5.00%
Report Date
Aug 6, 2024
EPS Beat/Miss
-12.4%
Price Before
$2.80
Price After
$2.94
Avg Beat Reaction+0.29%
Avg Miss Reaction-0.06%
Beat Rate4 / 8 quarters
Largest Move-8.06% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NERV ends December
Minerva Neurosciences, Inc. (NERV) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.17 — missing the analyst consensus of $-0.13 by -30.8%. The next NERV earnings date is expected around September 1, 2026.
Each quarter, investors track NERV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NERV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NERV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NERV earnings · 5 questionsMinerva Neurosciences, Inc.'s next earnings report is expected around September 1, 2026. NERV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NERV historically reports after market close (AMC).
NERV earnings datewhen is NERV earningsNERV next earnings datewhen does NERV report earningsNERV earnings calendar
▸ Source: FMP · Minerva Neurosciences, Inc. SEC filings · US GAAP · Minerva Neurosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026